Clinical trials: Benign Prostatic Hyperplasia
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Prostatic Hyperplasia
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved…
- Trial name
- NCT02244268
- Testing
- ALNA®
- Volunteers
- 3,629 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT06110923
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia, BPH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Trial name
- NCT01846793
- Testing
- NX-1207
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- Nymox Corporation
Benign Prostatic Hyperplasia
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg…
- Trial name
- NCT00540124
- Testing
- Tadalafil, Tamsulosin
- Where
- 5 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Prostatic Hyperplasia
Prospective Sexual Function Study for BPH Subjects
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo.
- Trial name
- NCT01777269
- Testing
- Dutasteride plus tamsulosin
- Where
- 67 sites in Australia, France and 5 more
- Volunteers
- 489 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign…
- Trial name
- NCT01967251
- Testing
- Udenafil
- Where
- 8 sites in Mexico
- Sponsor
- Takeda
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Safety and Feasibility of the XFLO Expander System (Mercury)
To demonstrate the safety and feasibility of the Mercury Expander system and procedure to treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia.
- Trial name
- EXPANDER-1 (NCT03758222)
- Testing
- XFLO Expander System
- Where
- 5 sites in Australia, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- MedeonBio, Inc.
BPH/LUTS/Sexual Functions
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive…
- Trial name
- NCT00542165
- Testing
- Alfuzosin
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Sanofi
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.
- Trial name
- MCS-2-TWN-c (NCT01002274)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
The goal of this clinical trial is to learn if Longidaze works to treat lower urinary tract symptoms in adult males with benign prostatic hyperplasia. It will also learn about the safety of Longidaze.
- Trial name
- ADAM (NCT06568718)
- Testing
- bovhyaluronidase azoximer, tamsulosin
- Where
- 3 sites in Russia
- Volunteers
- 229 people
- Sponsor
- NPO Petrovax
Benign Prostatic Hyperplasia
Temperature Mapping of the Prostate With the Wallterm™ System
To measure intra-prostatic temperatures and evaluate the shape and size of necrotic lesions achieved under the standard treatment protocol in men with benign prostatic hyperplasia (BPH).
- Trial name
- WT-DK-TMW08 (NCT00662350)
- Testing
- The Wallterm™ System
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Pnn Medical A/S